Evidence map›Paper›PMID 38722832›Full record

Trial reportPloS one2024

Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial.

G Justus Hofmeyr, Mandisa Singata-Madliki, Joanne Batting, Petrus Steyn, Katherine K Thomas, Rodal Issema, Ivana Beesham, Enough Mbatsane, Charles Morrison, Jen Deese and 8 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

G Justus HofmeyrUniversity of Botswana, Gaborone, Botswana.
Mandisa Singata-MadlikiEffective Care Research Unit, University of Witwatersrand, University of Fort Hare, East London, South Africa.
Joanne BattingEffective Care Research Unit, University of Witwatersrand, University of Fort Hare, East London, South Africa.
Petrus SteynUNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Geneva, Switzerland.
Katherine K ThomasDepartment of Global Health, University of Washington, Seattle, Washington, United States of America.
Rodal IssemaDepartment of Global Health, University of Washington, Seattle, Washington, United States of America.
Ivana BeeshamFaculty of Health Sciences, Department of Obstetrics and Gynaecology, MatCH Research Unit (MRU), University of the Witwatersrand, Durban, South Africa.ORCID https://orcid.org/0000-0003-4889-8123
Enough MbatsaneSetshaba Research Centre, Pretoria, South Africa.
Charles MorrisonFHI 360, Durham, North Carolina, United States of America.
Jen DeesePfizer Inc., Collegeville, Pennsylvania, United States of America.
Jenni SmitFaculty of Health Sciences, Department of Obstetrics and Gynaecology, MatCH Research Unit (MRU), University of the Witwatersrand, Durban, South Africa.
Neena PhilipMailman School of Public Health, ICAP at Columbia University, New York, New York, United States of America.ORCID https://orcid.org/0000-0001-5816-8197
Thesla Palanee-PhillipsDepartment of Epidemiology, University of Washington, Seattle, Washington, United States of America.ORCID https://orcid.org/0000-0002-0052-5830
Krishnaveni ReddyWits Reproductive Health and HIV Institute, School of Public Health, University of the Witwatersrand, Johannesburg, Gauteng, South Africa.
Maricianah OnonoKenya Medical Research Institute, Centre for Microbiology Research, Kisumu, Kenya.
Timothy D MastroFHI 360, Durham, North Carolina, United States of America.
Jared M BaetenDepartment of Global Health, University of Washington, Seattle, Washington, United States of America.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundContraceptive use has complex effects on sexual behaviour and mood, including those related to reduced concerns about unintended pregnancy, direct hormonal effects and effects on endogenous sex hormones. We set out to obtain robust evidence on the relative effects of three contraceptive methods on sex behaviours, which is important for guiding contraceptive choice and future contraceptive developments.

methodsThis is a secondary analysis of data from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) randomized trial in which 7,829 HIV-uninfected women from 12 sites in Eswatini, Kenya, South Africa and Zambia seeking contraception were randomly assigned to intramuscular depot-medroxyprogesterone acetate (DMPA-IM), the copper intrauterine device (Cu-IUD) or the levonorgestrel (LNG) implant. Data collected for 12 to 18 months using 3-monthly behavioural questionnaires that relied on recall from the preceding 3 months, were used to estimate relative risk of post-baseline sex behaviours, as well as sexual desire and menstrual bleeding between randomized groups using modified Poisson regression.

resultsWe observed small but generally consistent effects wherein DMPA-IM users reported lower prevalence of specified high risk sexual behaviours than implant users than Cu-IUD users (the '>' and '<' symbols indicate statistically significant differences): multiple sex partners 3.6% < 4.8% < 6.2% respectively; new sex partner 3.0% < 4.0% <5.3%; coital acts 16.45, 16.65, 17.12 (DMPA-IM < Cu-IUD); unprotected sex 65% < 68%, 70%; unprotected sex past 7 days 33% <36%, 37%; sex during vaginal bleeding 7.1%, 7.1% < 8.9%; no sex acts 4.1%, 3.8%, 3.4% (DMPA-IM > Cu-IUD); partner has sex with others 10% < 11%, 11%. The one exception was having any sex partner 96.5%, 96.9% < 97.4% (DMPA-IM < Cu-IUD). Decrease in sexual desire was reported by 1.6% > 1.1% >0.5%; amenorrhoea by 49% > 41% >12% and regular menstrual pattern by 26% <35% < 87% respectively.

conclusionsThese findings suggest that women assigned to DMPA-IM may have a modest decrease in libido and sexual activity relative to the implant, and the implant relative to the Cu-IUD. We found more menstrual disturbance with DMPA-IM than with the implant (and as expected, both more than the Cu-IUD). These findings are important for informing the contraceptive choices of women and policymakers and highlight the need for robust comparison of the effects of other contraceptive methods as well.

Indexed as

Intrauterine Devices, CopperLevonorgestrelMedroxyprogesterone AcetateSexual BehaviorAdolescentAdultContraceptionContraceptive Agents, FemaleDrug ImplantsFemaleHumansInjections, IntramuscularYoung AdultContraceptive Agents, FemaleDrug ImplantsLevonorgestrelMedroxyprogesterone Acetate

Identifiers

PMID38722832
PMCPMC11081305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.